Stock JNJB34 JOHNSON & JOHNSON
Add to a list
To use this feature you must be a member
Log inSign up

Financials Johnson & Johnson Sao Paulo

Equities

JNJB34

BRJNJBBDR002

Pharmaceuticals

Market Closed - Sao Paulo
Other stock markets
 04:05:00 2024-07-17 pm EDT 		5-day change 1st Jan Change
57.34 BRL +12.50% Intraday chart for Johnson & Johnson +6.50% +13.77%
Jul. 17 Dow Closes at Record, Nasdaq Slides as Markets Parse Fed Governor Remarks, Earnings MT
Jul. 17 Dow Closes at Record High as Nasdaq Plunges; Markets Parse Fed Governor Remarks, Earnings, Trade Threats MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 383,911 414,310 450,358 461,849 377,317 376,838 - -
Enterprise Value (EV) 1 392,320 424,391 452,501 477,989 383,722 378,260 364,558 349,844
P/E ratio 25.9 x 28.6 x 21.9 x 26.2 x 11.4 x - 17.5 x 16.1 x
Yield 2.57% 2.53% 2.45% 2.52% 3% 3.14% 3.22% 3.36%
Capitalization / Revenue 4.68 x 5.02 x 4.8 x 4.86 x 4.43 x 4.25 x 4.13 x 3.97 x
EV / Revenue 4.78 x 5.14 x 4.83 x 5.03 x 4.51 x 4.27 x 3.99 x 3.69 x
EV / EBITDA 14 x 15.6 x 12.4 x 14.6 x 12.6 x 12.6 x 11.8 x 10.7 x
EV / FCF 19.7 x 21 x 22.9 x 27.8 x 21 x 17.2 x 16.1 x 14.9 x
FCF Yield 5.08% 4.76% 4.37% 3.6% 4.76% 5.81% 6.22% 6.73%
Price to Book 6.46 x 9.53 x 6.08 x 6.13 x 5.84 x 5.35 x 4.81 x 4.28 x
Nbr of stocks (in thousands) 2,631,872 2,632,543 2,632,597 2,614,484 2,407,279 2,406,679 - -
Reference price 2 145.9 157.4 171.1 176.6 156.7 156.6 156.6 156.6
Announcement Date 1/22/20 1/26/21 1/25/22 1/24/23 1/23/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 82,059 82,584 93,775 94,943 85,159 88,566 91,307 94,828
EBITDA 1 27,979 27,145 36,634 32,630 30,414 29,950 30,820 32,586
EBIT 1 25,593 24,574 29,244 29,965 27,460 27,511 29,638 31,225
Operating Margin 31.19% 29.76% 31.19% 31.56% 32.25% 31.06% 32.46% 32.93%
Earnings before Tax (EBT) 1 17,328 16,497 22,776 21,725 15,062 25,062 25,974 -
Net income 15,119 14,714 20,878 17,941 35,153 - 21,602 23,455
Net margin 18.42% 17.82% 22.26% 18.9% 41.28% - 23.66% 24.73%
EPS 5.630 5.510 7.810 6.730 13.72 - 8.953 9.720
Free Cash Flow 1 19,918 20,189 19,758 17,185 18,248 21,993 22,688 23,529
FCF margin 24.27% 24.45% 21.07% 18.1% 21.43% 24.83% 24.85% 24.81%
FCF Conversion (EBITDA) 71.19% 74.37% 53.93% 52.67% 60% 73.43% 73.61% 72.21%
FCF Conversion (Net income) 131.74% 137.21% 94.64% 95.79% 51.91% - 105.03% 100.31%
Dividend per Share 2 3.750 3.980 4.190 4.450 4.700 4.923 5.037 5.265
Announcement Date 1/22/20 1/26/21 1/25/22 1/24/23 1/23/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 24,804 23,426 24,020 23,791 23,706 24,746 25,530 21,351 21,395 21,383 22,447 22,215 22,464 22,118 23,080
EBITDA 1 7,939 9,305 9,011 9,299 7,804 8,880 8,912 8,071 6,333 7,973 8,129 6,809 7,214 8,310 8,635
EBIT 1 6,096 7,536 7,267 7,614 7,093 8,204 8,189 7,374 5,638 7,236 7,712 5,965 6,629 7,509 7,710
Operating Margin 24.58% 32.17% 30.25% 32% 29.92% 33.15% 32.08% 34.54% 26.35% 33.84% 34.36% 26.85% 29.51% 33.95% 33.41%
Earnings before Tax (EBT) 1 4,836 5,862 5,840 5,822 4,201 -737 6,762 5,217 4,826 6,440 5,748 5,166 5,800 - -
Net income 1 4,736 - - 4,458 3,520 -68 5,144 26,028 4,049 5,354 4,686 - - 5,383 5,433
Net margin 19.09% - - 18.74% 14.85% -0.27% 20.15% 121.91% 18.92% 25.04% 20.88% - - 24.34% 23.54%
EPS 2 1.770 1.930 1.800 1.680 1.330 -0.0300 1.960 10.21 1.670 2.200 1.930 - - 2.231 2.252
Dividend per Share 2 1.060 1.060 1.130 1.130 1.130 1.130 1.190 1.190 1.190 1.190 1.225 1.205 1.225 1.221 1.221
Announcement Date 1/25/22 4/19/22 7/19/22 10/18/22 1/24/23 4/18/23 7/20/23 10/17/23 1/23/24 4/16/24 7/17/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 8,409 10,081 2,143 16,140 6,405 1,422 - -
Net Cash position 1 - - - - - - 12,280 26,994
Leverage (Debt/EBITDA) 0.3005 x 0.3714 x 0.0585 x 0.4946 x 0.2106 x 0.0475 x - -
Free Cash Flow 1 19,918 20,189 19,758 17,185 18,248 21,993 22,688 23,529
ROE (net income / shareholders' equity) 39.1% 34.9% 38.2% 23.8% 34.9% 35.7% 36.3% 35.3%
ROA (Net income/ Total Assets) 15% 12.9% 14.7% 9.71% 14.3% 13.9% 13.8% 14%
Assets 100,753 114,174 142,233 184,698 245,525 - 156,536 167,535
Book Value Per Share 2 22.60 16.50 28.20 28.80 26.90 29.30 32.50 36.60
Cash Flow per Share 8.720 8.810 8.750 7.960 8.900 - - -
Capex 1 3,498 3,347 3,652 4,009 4,543 4,147 3,944 4,078
Capex / Sales 4.26% 4.05% 3.89% 4.22% 5.33% 4.68% 4.32% 4.3%
Announcement Date 1/22/20 1/26/21 1/25/22 1/24/23 1/23/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Johnson & Johnson

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
156.6 USD
Average target price
171.5 USD
Spread / Average Target
+9.52%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+55.35% 848B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.64% 627B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.47% 318B
ABBVIE INC. Stock AbbVie Inc.
+13.10% 299B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.51% 243B
NOVARTIS AG Stock Novartis AG
+16.72% 225B
AMGEN INC. Stock Amgen Inc.
+16.54% 179B
PFIZER, INC. Stock Pfizer, Inc.
+4.31% 167B
SANOFI Stock Sanofi
+2.52% 125B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. JNJ Stock
  4. JNJB34 Stock
  5. Financials Johnson & Johnson